Author: George Underwood

The FDA has approved Celltrion and Pfizer’s biosmiliar of Johnson & Johnson’s Remicade (infliximab) for treating Crohn’s disease, ulcerative colitis, rheumatoid arthritis, psoriasis and arthritis of the spine – making it only the second biosimilar approved in the US.

Pfizer and Allergan are reportedly looking to jointly terminate their planned $160 billion merger following new US rules designed to curb so-called ‘tax inversion’ deals.

Increasing workloads for GPs and nurses are unsustainable, and general practice in England could be reaching saturation point, a new study published in The Lancet has suggested.

NHS England has launched a national programme to combat antibiotic overusage, which it describes it as “the world’s largest healthcare incentive scheme” to prevent antimicrobial resistance. 

US drugmaker Amarin has reached a settlement with the FDA allowing it to promote off-label use of its Vascepa (icosapent ethyl).